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Background: Leishmaniasis is a protozoan disease caused by parasites of the genus Leishmania, transmitted to
humans by sandflies. The diagnosis of leishmaniasis is often challenging as it mimics many other infectious or
malignant diseases. The disease can present in three ways: cutaneous, mucocutaneous, or visceral leishmaniasis,
which rarely occur together or consecutively.
Case presentation: The patient was a 52 years old immunosuppressed Belgian woman with a long history of severe
rheumatoid arthritis. She underwent bone marrow biopsy to explore thrombocytopenia. Diagnosis of visceral
leishmaniasis was made by identification of Leishman Donovan (LD) bodies in macrophages. Treatment with liposomal
amphotericin B was successful. She later developed cutaneous leishmaniasis treated with amphotericin B lipid complex.
She next presented with relapsing cutaneous lesions followed by rapidly progressing lymphadenopathies. Biopsy
confirmed the diagnosis of leishmaniasis. Treatments by miltefosine, amphotericin B, N-methyl-glucamine antimoniate
were subsequently initiated. She later presented a recurrent bone marrow involvement treated with intramuscular
paromomycin and miltefosine. She died two years later from leukemia. At the time of death, she presented with a
mucosal destruction of the nose. A Leishmania-specific PCR (Polymerase Chain Reaction) identified L. infantum as
etiological agent.
Conclusions: Clinicians should be aware of the potential concomitant or sequential involvement of multiple anatomic
localizations of Leishmania in immunosuppressed patients.
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MicrobiologyBackground
Leishmaniasis is a protozoan disease caused by more
than 20 species of the genus Leishmania and transmitted
to humans by the bite of sandflies. The diagnosis of
leishmaniasis is often challenging as it mimics many
other infectious or malignant diseases.
Three patterns of infection are described: cutaneous
(CL), mucosal (ML) and visceral leishmaniasis (VL). CL
usually presents as papules, plaques, ulcers or nodules
and occurs mostly on exposed areas of the skin. ML is
characterized by destructive lesions mainly affecting the* Correspondence: gdarcis@chu.ulg.ac.be
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black fever, is a potentially fatal disease. Symptoms in-
clude fever, weight loss, hepato- and splenomegaly.
Anemia and thrombocytopenia occur when parasites ac-
cumulate in the bone marrow. VL widely predominates
in poor rural and suburban areas of India, Bangladesh,
Sudan, Ethiopia and Brazil while CL is more broadly dis-
tributed and occurs in the south and central American
countries, the Mediterranean basin, and from the Middle
East to Central Asia [1]. ML is mostly observed in Latin
America.
L. infantum is well recognized as the etiological
agent of VL in southern Europe and is much less
commonly reported as a cause of CL [2]. Mucosalle is distributed under the terms of the Creative Commons Attribution 4.0
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Concomitant or consecutive cutaneous or mucosal
with visceral clinical manifestations of leishmaniasis
have been seldom described. Herein we report the
first case of an immunosuppressed woman who pre-
sented the entire spectrum of the disease and we dis-
cuss its clinical significance.
Case presentation
The patient was a Belgian woman born in 1956 with a
long history of severe rheumatoid arthritis (RA) compli-
cated by vasculitis and cryoglobulinemia, and treated
with etanercept, ciclosporin and methylprednisolone.
She had only travelled to Spain in 2004.
In 2006 she developed mild anemia, thrombocytopenia
and splenomegaly which were interpreted as manifesta-
tions of Felty syndrome. Screening for infectious diseases
including HIV was negative. In March 2007 she was di-
agnosed with stage IIB EBV-negative classical Hodgkin
lymphoma, based on an inguinal lymph node biopsy.
The patient was treated with four cycles of C-MOPP
(cyclophosphamide, vincristine, procarbazine and pred-
nisone) plus radiation therapy targeting the left inguinal
region. While undergoing chemotherapy she had persist-
ent neutropenia (neutrophils: 1390/mm3, norm: 2100–
8000/mm3) thrombocytopenia (thrombocytes: 43,000/
mm3, norm: 170,000–400,000/mm3) and increasing
splenomegaly. The markedly enlarged spleen (850 g) was
surgically removed and showed marked histiocytic infil-
trate of the red pulp, hemophagocytosis, and reactive
polytypic plasma cells. Since thrombocytopenia was still
increasing, she underwent bone marrow biopsy and aspir-
ate in 2008. Diagnosis of VL was made by identification ofFig. 1 Visceral and cutaneous leishmaniasis. a. Bone marrow aspirate: May
macrophages with abundant cytoplasm containing innumerable Leishmani
pulp comprising a prominent infiltrate of histiocytes and plasma cells; the h
by a clear halo, suggestive of Leishman bodies (hematoxylin eosin staining
in the upper dermis consisting of predominantly large histiocytes, plasma c
multiple gray-blue bodies within the vacuolated cytoplasm of histiocytes (hLeishman Donovan (LD) bodies in macrophages after
Giemsa staining (Fig. 1a). Serum antibody tests (indirect
immunofluorescence) were positive for L. braziliensis, L.
infantum and L. tropica due to cross reactions between
species. In retrospect, Leishmania was also detected in the
splenic sections (Fig. 1b).
Treatment with liposomal amphotericin B (4 mg/kg
for 10 days) was successful. Due to immunosuppression,
secondary prophylaxis with monthly amphotericin B was
given as proposed for patients with HIV coinfection [6],
but stopped after only 2 doses because of medical costs
issues.
In 2009, etanercept treatment was replaced by rituxi-
mab twice a year. She developed multiple cutaneous
nodular lesions mainly located in the left elbow and the
buttocks. Histopathology was performed. LD bodies
were evident within macrophages (Fig. 1c). Amphoteri-
cin B lipid complex treatment (5 mg/kg for 10 days)
allowed for complete healing of the lesions. Secondary
prophylaxis with monthly amphotericin B was again
given. In 2010, despite secondary prophylaxis, she pre-
sented with relapsing cutaneous lesions followed by
rapidly progressing lymphadenopathies (cervical, subcla-
vicular, sub- and sus-diaphragmatic) on PET/CT. Lymph
node biopsy showed massive macrophagic infiltrate
comprising LD bodies. Rituximab was stopped. Treat-
ment by miltefosine (50 mg bd) was instituted but then
stopped because of digestive intolerance. Amphotericin
B was reintroduced but failed, probably because of re-
sistance. N-methyl-glucamine antimoniate (20 mg/kg),
more recently used with success by other groups when
multiple failures or relapses occur after treatment with
liposomal amphotericin B [7], was subsequently initiatedGrunwald Giemsa (original magnification: ×1000) showing two
a amastigotes. b. Spleen histology: High power view of the splenic red
istiocytes show numerous cytoplasmic punctate bodies surrounded
; original magnification: ×400). c. Cutaneous histology: Diffuse infiltrate
ells and a few lymphocytes. Protozoan leishmania, visualized as
ematoxylin eosin staining)
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de pointes. Cutaneous lesions disappeared and PET/CT
showed an almost full metabolic response with dis-
appearance of adenopathy. However, she later presented
thrombocytopenia due to recurrent bone marrow in-
volvement which was successfully treated with intramus-
cular paromomycin (15 mg/kg) and miltefosine (50 mg
bd) for 28 days.
In 2012, she presented few relapsing cutaneous lesions
requiring topical treatment. Two years later she was di-
agnosed with chronic myelomonocytic leukemia and
died in 2015 from blastic crisis. At the time of death, she
presented with a mucosal destruction of the nose clearly
visible on a CT scan performed a few days before she
died (Fig. 2). Autopsy was performed to confirm the
mucosal involvement by Leishmania. A real-time
Leishmania-specific PCR [8] performed on the nasal
biopsy was positive (cycle threshold value 23,87) and
molecular HSP70-typing identified L. infantum as
etiological agent [9].
Discussion and conclusion
L. infantum is the etiological agent of VL in Europe
where it is endemic in the Mediterranean region. Dogs
are considered the major reservoir and sandflies are the
only proven vectors of this zoonotic protozoan disease
[10]. The incidence of VL associated with the transmission
of L. infantum has been declining in many foci where
living standards have improved. ImmunosuppressionFig. 2 Mucosal leishmaniasis. CT scan showing left maxillary sinusitis
and centimetric perforation of the nasal septal cartilageconfers a higher risk of clinical disease due to L. infantum.
While visceral and cutaneous manifestations of L. infan-
tum are quite common, mucosal presentation is rare and
has been only sporadically described. Association of
cutaneous and visceral involvement has been reported
in patients co-infected with HIV [11]. Simultaneous
mucosal and visceral manifestations have been de-
scribed in corticosteroid-treated patients [12]. Inter-
estingly, Souza et al. very recently reported patients
from an endemic area of leishmaniasis, treated for
RA, who presented with recurrent CL or ML [13].
However, we believe that this case report is the first
example of L. infantum infection with recurrent vis-
ceral, cutaneous and finally mucosal involvement. The
development of all these clinical manifestations has
been facilitated by immunosuppressive therapy re-
quired to control a severe RA.
This case also demonstrates that the diagnosis of
leishmaniasis is often challenging as it mimics many
other infectious or malignant diseases. The scarcity of
leishamniasis in non-endemic settings like Belgium
makes the diagnosis even more difficult and contributed
to the delay before diagnosis. Thrombocytopenia was
first thought related to hypersplenism. Following
splenectomy, persistent thrombocytopenia could be
caused by numerous conditions and manifestations of
VL are often misinterpreted as symptoms of malig-
nancies, other infectious or autoimmune diseases such
as systemic lupus erythematosus [14]. Discussion of
cutaneous lesions is also challenging since CL mimics
other infectious conditions including mycobacteriosis
or inflammatory diseases such as nummular derma-
titis or psoriasis. Moreover, cutaneous lesions could
have been considered as post-kala-azar dermal leish-
maniasis. However, the recurrence of cutaneous le-
sions together with VL relapse as well as the localized
nature of the cutaneous lesions rather suggests CL.
Diagnosis of mucosal lesions located in the nose is
complex since lesions often mimic neoplastic pro-
cesses or necrotizing vasculitis [15].
In conclusion, this exceptional case highlights that cli-
nicians should be aware of the potential concomitant or
sequential involvement of multiple anatomic localiza-
tions of leishmaniasis in immunosuppressed patients.
This observation is particularly relevant given the risk of
emergence of leishmaniasis in Europe consequent to the
increasing worldwide travelling of humans and domestic
dogs, increasing flow of migrants from the Middle East
to Europe and climatic changes [16]. Indeed, the occur-
rence of sandflies in Central Europe and in adjacent re-
gions of Western-Europe is established and sandflies
have been found in several parts of Germany and
Belgium [17]. Thus local acquisition of leishmaniasis in
Belgium is not totally excluded.
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